Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Financing Activities: 2012-2024

Historic Cash from Financing Activities for Ocular Therapeutix (OCUL) over the last 13 years, with Dec 2024 value amounting to $332.1 million.

  • Ocular Therapeutix's Cash from Financing Activities rose 147.87% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.9 million, marking a year-over-year decrease of 73.18%. This contributed to the annual value of $332.1 million for FY2024, which is 95.56% up from last year.
  • As of FY2024, Ocular Therapeutix's Cash from Financing Activities stood at $332.1 million, which was up 95.56% from $169.8 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Cash from Financing Activities registered a high of $332.1 million during FY2024, and its lowest value of $1.5 million during FY2022.
  • Its 3-year average for Cash from Financing Activities is $167.8 million, with a median of $169.8 million in 2023.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first slumped by 98.75% in 2021, then spiked by 11,580.06% in 2023.
  • Ocular Therapeutix's Cash from Financing Activities (Yearly) stood at $228.0 million in 2020, then tumbled by 98.75% to $2.9 million in 2021, then slumped by 49.00% to $1.5 million in 2022, then surged by 11,580.06% to $169.8 million in 2023, then surged by 95.56% to $332.1 million in 2024.